Ibrilatazar

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameIbrilatazar
Drug Alias NameLP-10218ABTL-0812LAM-182SCLN-0812
ClassificationSmall molecules
Mechanisms of ActionDihydrofolate reductase inhibitorsPeroxisome proliferator-activated receptor α agonistsPeroxisome proliferator-activated receptor γ agonists +[4] 
TargetsDihydrofolate reductasePeroxisome proliferator-activated receptor αPeroxisome proliferator-activated receptor γ
Therapy Area/IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceIsrael +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaIND
Originator CompaniesLipopharma Therapeutics Sl
China Registration ClassN/A

Develop Information

Active CompaniesSpanish Ministry Of Science And InnovationSciclone PharmaceuticalsAGC Pharma Chemicals Europe SLU +[7] 
Inactive CompaniesN/A
Active IndicationsEndometrial NeoplasmsPancreatic NeoplasmsCarcinoma, Squamous Cell
Inactive IndicationsCarcinoma, Non-Small-Cell LungNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A